Investor profile
Inkef Capital
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Inkef is an early-stage venture capital firm based in Amsterdam, investing in two core sectors: Healthcare and Technology. Within Healthcare, the firm focuses on Therapeutics, Digital Health, and Medical Devices. Within Technology, priority areas include the Future of Commerce, Future of Work, Data & AI Stack, Future of Software Engineering, Fintech, and DeepTech. The sweet spot is Seed and Series A rounds, with selective participation in earlier or later stages for exceptional companies. Founded in 2010 and backed by Dutch pension fund ABP/APG, Inkef takes a patient, long-term approach — positioning itself as a partner for the long haul. The firm's goal is to help build companies, not valuations, believing that true value and sustainable returns can only be created with a long-term strategic vision. Inkef supports entrepreneurs from the very early stages of a technology or life science venture, helping them build ideas into successful international businesses with global footprints.
Notable quotes
“Today is my first day, a new job: Managing Partner at Inkef Capital. After 15 years APG Asset Management it is time for a new challenge. Generating value to our investor and Dutch society.”
“We backed TargED early because the need is real: thrombotic disease remains one of the most underserved areas in medicine.”
“In 2020, the quantum space was still finding its footing. Most capital was flowing toward modalities that made for good demos but had no credible path to manufacturing at scale. Our team saw something different.”
Team
Frank Lansink
Partner (Tech Practice)
Ivan Burkov
Junior Partner
Ryan Sarver
Venture Partner
Thijs Cohen Tervaert
Partner
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Quantum Motion | Series C | $160m | 2026-05-07 |
| TargED Biopharmaceuticals | Series A | $25m | 2025-12-16 |
| Salvia BioElectronics | Series B | $60m | 2025-05-27 |
| Draupnir Bio | Seed | $13m | 2024-07-23 |
| iOnctura | Series B | $86m | 2024-06-20 |
| NMD Pharma | Series B | $82m | 2023-11-15 |
| GitLab | Series D | — | — |
| Remote | Series A | — | — |
| EclecticIQ | Series B | $24m | — |
| Silverflow | Series B | $40m | 2026-03-05 |
Frequent co-investors
Fit check
Is Inkef Capital a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit